Astellas Pharma | 4503

Stock Price
2,441.00
Daily Change
20.00 0.83%
Monthly
11.69%
Yearly
70.28%
Q1 Forecast
2,057.60



Peers Price Chg Day Year Date
M3 1,739.50 -20.50 -1.16% 26.33% Feb/06
Kyowa Hakko Kirin 2,402.50 32.50 1.37% 13.49% Feb/06
Takeda 5,517.00 -75.00 -1.34% 33.36% Feb/06
Astellas Pharma 2,441.00 20.00 0.83% 70.28% Feb/06
Sumitomo Dainippon 2,229.50 -89.00 -3.84% 191.44% Feb/06
Shionogi 3,393.00 -35.00 -1.02% 56.40% Feb/06
Chugai Pharma 8,608.00 -517.00 -5.67% 24.36% Feb/06
Eisai 4,482.00 -78.00 -1.71% -0.53% Feb/06
Terumo 2,045.00 14.00 0.69% -27.60% Feb/06
Daiichi Sankyo 2,869.00 -65.00 -2.22% -25.15% Feb/06

Indexes Price Day Year Date
JP225 54254 435.64 0.81% 39.88% Feb/06

Astellas Pharma traded at 2,441.00 this Friday February 6th, increasing 20.00 or 0.83 percent since the previous trading session. Looking back, over the last four weeks, Astellas Pharma gained 11.69 percent. Over the last 12 months, its price rose by 70.28 percent. Looking ahead, we forecast Astellas Pharma to be priced at 2,057.60 by the end of this quarter and at 1,818.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.